This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Molecular Partners (MOLN) and Park Dental Partners, Inc. (PARK)

Tipranks - Tipranks - Fri Jun 5, 10:52PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Disc Medicine (IRON), Molecular Partners (MOLN) and Park Dental Partners, Inc. (PARK) with bullish sentiments.

Claim 55% Off TipRanks

Disc Medicine (IRON)

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Disc Medicine on June 2. The company’s shares closed last Thursday at $71.11.

According to TipRanks.com, Smith is a top 100 analyst with an average return of 47.8% and a 54.6% success rate. Smith covers the Healthcare sector, focusing on stocks such as Cartesian Therapeutics, Viridian Therapeutics, and Spyre Therapeutics. ;'>

Disc Medicine has an analyst consensus of Strong Buy, with a price target consensus of $103.14, representing a 46.3% upside. In a report issued on June 2, LifeSci Capital also maintained a Buy rating on the stock with a $100.00 price target.

See the top stocks recommended by analysts >>

Molecular Partners (MOLN)

Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Molecular Partners on June 2. The company’s shares closed last Thursday at $3.93, close to its 52-week low of $3.32.

According to TipRanks.com, Chang is a 4-star analyst with an average return of 5.0% and a 36.2% success rate. Chang covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Replimune Group, and Nanobiotix. ;'>

Molecular Partners has an analyst consensus of Strong Buy, with a price target consensus of $11.00.

Park Dental Partners, Inc. (PARK)

In a report issued on June 2, Matt Hewitt from Craig-Hallum maintained a Buy rating on Park Dental Partners, Inc.. The company’s shares closed last Thursday at $18.64.

According to TipRanks.com, Hewitt is a 1-star analyst with an average return of -1.5% and a 42.1% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Dyadic International, and Lifecore Biomedical. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Park Dental Partners, Inc..

Read More on IRON:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).